IHC–The need of the hour in classifying lung tumours effectively on guided biopsies!


Article PDF :

Veiw Full Text PDF

Article type :

Original Article

Author :

Vidya K, Sahil Saraf

Volume :

6

Issue :

4

Abstract :

Introduction: IHC forms an effective supplement to the morphological diagnosis in the emphatic categorisation of the lung carcinomas, especially the undifferentiated NSCLC i.e NOS types, which is very essential for an effective therapy. In this regard P63 and TTF-1 are considered the most important markers in subclassifying the NSCLC. P63 is a sensitive marker for squamous cell carcinoma, and TTF-1 for adenocarcinoma. Objectives: 1) Immunohistochemical study of guided biopsies of the lung using TTF-1 and p63 markers. 2) To improve diagnostic clarity in poorly differentiated tumours. Materials and Methods: Forty guided biopsies which were proved malignant on histopathology were taken from August 2012 to August 2014, at a tertiary health care centre, Bangalore. Results: Of the total 40 cases, 13 cases (32.5%) were diagnosed as NSCLC NOS because of their inconclusive morphology on H&E for any particular subtype. Following immunohistochemistry, their number reduced to 4 (10%), from a massive 13 (32.5%) cases. One case of NSCLC favor SCC was rediagnosed as NSCLC favor adenocarcinoma, because it was positive for TTF-1 and negative for p63, and one case of LCNEC being rediagnosed as NSCLC favor adenocarcinoma as it was negative for both synaptophysin and p63, but positive for TTF-1. Conclusion: In this study p63 stained 87% of the cases that were suspected to be squamous cell carcinoma and TTF-1 stained all the 7 cases suspected to be adenocarcinoma on a preliminary H&E report. Further these two stains were able to categorise the 9 out of the 13 cases of NSCLC NOS effectively into specific types. Abbreviations: SCLC - small cell lung carcinoma NSCLC- Non-small cell lung carcinoma; NOS, not otherwise specified; LCNEC-Large cell neuroendocrine carcinoma IHC: Immunohistochemitry.

Keyword :

 NSCLC, Lung carcinoma, P63, TTF1, IHC.